JP2024528066A - ハンチントン病を処置するためのヘテロアリール化合物 - Google Patents

ハンチントン病を処置するためのヘテロアリール化合物 Download PDF

Info

Publication number
JP2024528066A
JP2024528066A JP2024505314A JP2024505314A JP2024528066A JP 2024528066 A JP2024528066 A JP 2024528066A JP 2024505314 A JP2024505314 A JP 2024505314A JP 2024505314 A JP2024505314 A JP 2024505314A JP 2024528066 A JP2024528066 A JP 2024528066A
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
day
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024505314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528066A5 (enExample
Inventor
スレシュ バブ
ラウフル アラム
アヌラダ バタチャリア
グアンミン チェン
マシュー エス イーストウッド
セイエドモルテザ ホセイニ
ヤオ ジャン
ギャリー ミッチェル カープ
ヨン－チュン ムン
ジャナ ナラシムハン
ホンユ レン
ナディヤ シドレンコ
マシュー ジー ウォル
ナンジン ジャン
Original Assignee
ピーティーシー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピーティーシー セラピューティクス， インコーポレイテッド filed Critical ピーティーシー セラピューティクス， インコーポレイテッド
Publication of JP2024528066A publication Critical patent/JP2024528066A/ja
Publication of JP2024528066A5 publication Critical patent/JP2024528066A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2024505314A 2021-07-30 2022-07-29 ハンチントン病を処置するためのヘテロアリール化合物 Pending JP2024528066A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203761P 2021-07-30 2021-07-30
US63/203,761 2021-07-30
PCT/US2022/038870 WO2023009816A1 (en) 2021-07-30 2022-07-29 Heteroaryl compounds for treating huntington's disease

Publications (2)

Publication Number Publication Date
JP2024528066A true JP2024528066A (ja) 2024-07-26
JP2024528066A5 JP2024528066A5 (enExample) 2025-07-31

Family

ID=83149486

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024505314A Pending JP2024528066A (ja) 2021-07-30 2022-07-29 ハンチントン病を処置するためのヘテロアリール化合物

Country Status (16)

Country Link
US (1) US20240336613A1 (enExample)
EP (1) EP4377317A1 (enExample)
JP (1) JP2024528066A (enExample)
KR (1) KR20240054264A (enExample)
CN (1) CN118159539A (enExample)
AR (1) AR126612A1 (enExample)
AU (1) AU2022320725A1 (enExample)
CA (1) CA3227287A1 (enExample)
CL (1) CL2024000250A1 (enExample)
CO (1) CO2024000890A2 (enExample)
CR (1) CR20240043A (enExample)
IL (1) IL310440A (enExample)
MX (1) MX2024001417A (enExample)
PE (1) PE20240929A1 (enExample)
TW (1) TW202321247A (enExample)
WO (1) WO2023009816A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018282154B2 (en) 2017-06-05 2022-04-07 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
AU2019243048A1 (en) 2018-03-27 2020-10-15 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
IL279688B2 (en) 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
BR112020026534A2 (pt) 2018-06-27 2021-03-23 Ptc Therapeutics, Inc. Compostos de heteroarila para o tratamento da doença de huntington
CN114245794B (zh) 2019-05-13 2024-09-13 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
CN119451674A (zh) * 2022-06-15 2025-02-14 Ptc医疗公司 用于治疗亨廷顿病的杂环和杂芳基化合物
EP4719599A1 (en) 2023-06-02 2026-04-08 Merck Sharp & Dohme LLC 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020005873A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020005882A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020190793A1 (en) * 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020005873A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020005882A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020190793A1 (en) * 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing

Also Published As

Publication number Publication date
CA3227287A1 (en) 2023-02-02
TW202321247A (zh) 2023-06-01
KR20240054264A (ko) 2024-04-25
US20240336613A1 (en) 2024-10-10
CR20240043A (es) 2024-05-22
WO2023009816A1 (en) 2023-02-02
AR126612A1 (es) 2023-10-25
CL2024000250A1 (es) 2024-07-12
MX2024001417A (es) 2024-05-14
AU2022320725A1 (en) 2024-02-22
IL310440A (en) 2024-03-01
CO2024000890A2 (es) 2024-04-29
PE20240929A1 (es) 2024-04-30
EP4377317A1 (en) 2024-06-05
CN118159539A (zh) 2024-06-07

Similar Documents

Publication Publication Date Title
US12103926B2 (en) Compounds for treating huntington's disease
KR102823158B1 (ko) 헌팅턴병 치료를 위한 헤테로사이클릭 및 헤테로아릴 화합물
EP3645121B1 (en) Methods for treating huntington's disease
AU2022320725A1 (en) Heteroaryl compounds for treating huntington's disease
JP7799618B2 (ja) ハンチントン病を処置するための化合物
EP4539841A2 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
EA051950B1 (ru) Гетероарильные соединения для лечения болезни хантингтона
EA041957B1 (ru) Соединения для лечения болезни гентингтона
HK40116823A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
NZ794019A (en) Compounds for treating huntington's disease
HK40043148B (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
HK40043148A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250722

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260326